Brokers Issue Forecasts for ImmunityBio FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS forecast for ImmunityBio to a loss of $0.26 per share from a prior estimate of $0.40, while maintaining a Buy rating and $15 price target.
• Analyst sentiment is generally positive: six analysts rate the stock Buy and one rates it Sell, producing a consensus “Moderate Buy” rating and a $16 price target. Jefferies and Piper Sandler also recently raised or reaffirmed bullish targets.
• ImmunityBio’s latest quarterly loss of $0.22 per share missed estimates of $0.08, despite revenue of $51.24 million exceeding expectations. The stock opened at $8.77, while insiders own 66.1% of shares and institutional investors own 8.58%.

ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Equities research analysts at HC Wainwright upped their FY2026 EPS estimates for ImmunityBio in a research note issued on Thursday, October 15th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.26) per share for the year, up from their prior forecast of ($0.40). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for ImmunityBio's current full-year earnings is ($0.44) per share.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.14). The business had revenue of $51.24 million for the quarter, compared to analyst estimates of $49.70 million.

Other analysts also recently issued research reports about the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of ImmunityBio in a report on Tuesday, October 6th. Jefferies Financial Group upped their price target on ImmunityBio from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Wednesday, October 14th. Finally, Piper Sandler restated an "overweight" rating and set a $16.00 price target on shares of ImmunityBio in a research note on Wednesday, October 14th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, ImmunityBio has a consensus rating of "Moderate Buy" and a consensus price target of $16.00.

ImmunityBio Stock Performance

Shares of IBRX stock opened at $8.77 on Wednesday. The firm's 50 day moving average price is $8.61 and its 200-day moving average price is $7.99. ImmunityBio has a one year low of $1.95 and a one year high of $12.43. The firm has a market cap of $9.29 billion, a P/E ratio of -9.04 and a beta of 0.02.

Institutional Trading of ImmunityBio

A number of large investors have recently modified their holdings of the stock. Fortress Financial Solutions LLC purchased a new position in ImmunityBio in the third quarter worth approximately $105,000. Firethorn Wealth Partners LLC grew its holdings in ImmunityBio by 107.9% during the 3rd quarter. Firethorn Wealth Partners LLC now owns 25,475 shares of the company's stock worth $240,000 after acquiring an additional 13,219 shares in the last quarter. Courier Capital LLC increased its position in shares of ImmunityBio by 100.0% in the 3rd quarter. Courier Capital LLC now owns 112,000 shares of the company's stock valued at $1,057,000 after purchasing an additional 56,000 shares during the last quarter. GAMMA Investing LLC increased its position in shares of ImmunityBio by 262.2% in the 3rd quarter. GAMMA Investing LLC now owns 3,807 shares of the company's stock valued at $36,000 after purchasing an additional 2,756 shares during the last quarter. Finally, Collective Family Office LLC raised its holdings in shares of ImmunityBio by 2.6% in the 3rd quarter. Collective Family Office LLC now owns 161,254 shares of the company's stock valued at $1,522,000 after purchasing an additional 4,054 shares in the last quarter. Hedge funds and other institutional investors own 8.58% of the company's stock.

Insider Activity

In other ImmunityBio news, Director Cheryl Cohen sold 81,056 shares of the firm's stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total value of $851,088.00. Following the completion of the transaction, the director owned 100,309 shares of the company's stock, valued at $1,053,244.50. This trade represents a 44.69% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the business's stock in a transaction on Monday, October 5th. The stock was sold at an average price of $10.75, for a total transaction of $268,750.00. Following the completion of the transaction, the director owned 2,777,788 shares of the company's stock, valued at approximately $29,861,221. This trade represents a 0.89% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 66.10% of the company's stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body's immune response against cancer and infectious diseases. The company's approach combines immune-system modulators, cellular therapies, vaccines and other technologies intended to address multiple stages of the disease-treatment process.

Its lead product, Anktiva (nogapendekin alfa inbakicept-pmln, also known as N-803), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.